AssureRx Health Receives 2012 ACA Luis Villalobos Award for Innovation
Angel Capital Association Recognizes AssureRx Health For Leadership in Personalized Medicine for Behavioral Health
Mason, OH – March 12, 2012 – The Angel Capital Association, a trade association of leading angel investment groups in North America, recognized AssureRx Health Inc. as an innovative leader in personalized medicine technology with the 2012 Luis Villalobos Award.
This award recognizes the most ingenious and innovative idea recently financed by angel groups that are members of the Angel Capital Association (ACA). The award is named in honor of Mr. Villalobos, the founder of Tech Coast Angels, and an innovator in the angel investor field.
“This is a great honor considering the number of innovative startups across the country,” said James S. Burns, president and CEO of AssureRx Health. “The Luis Villalobos Award is a testament to our customers, employees and investors, who are passionate about the impact that our technology can have on patient care.”
“The Luis Villalobos Award recognizes angel portfolio companies that are startlingly innovative,” said Marianne Hudson, executive director of ACA. “AssureRx Health has created a solution based on cutting edge technology that helps clinicians significantly improve patient outcomes while offering improved efficiency and economics to the healthcare industry.” AssureRx Health received the award at the 2012 ACA Summit on March 7 in Austin, TX.
AssureRx Health is a personalized medicine company that specializes in pharmacogenomics – the study of genetic factors that influence an individual’s response to drug treatments. AssureRx Health is dedicated to helping clinicians determine the right drug for individual patients suffering from neuropsychiatric and other disorders.
Many of the estimated 25 percent of adults who will suffer from a mental disorder during their lives go through months or years of trial and error to find appropriate medications, with many of them discontinuing treatment without finding relief. While many FDA-approved medications exist to treat psychiatric disorders, clinicians can now use objective, evidence-based standards to select the right medication for each patient based on their genetic makeup.
“GeneSightRx®, our industry leading pharmacogenomic testing program, helps clinicians personalize medication treatment for behavioral health,” said Mr. Burns. “AssureRx Health is a model for the future of personalized medicine. The biology and genetic variability is so complex that you need advanced bioinformatics to put the information together in a clinically relevant and actionable way. Our goal is to provide pharmacogenomic products that can help transform the treatment of neuropsychiatric disorders.”
GeneSight is a laboratory developed pharmacogenomic test that uses cutting edge technology to measure and analyze clinically important genomic variants in the treatment of psychiatric disorders. The results of the GeneSight report can help a clinician understand the way a patient’s unique genomic makeup may affect certain psychiatric drugs. The analysis is based on pharmacogenomics, the study of genomic factors that influence an individual’s response to drug treatments, FDA approved manufacturer’s drug labels, peer-reviewed scientific and clinical publications, and proven drug pharmacology. Quick turnaround time, combined with a customized report of the patient’s genomic makeup, clinical experience and other factors can help a physician make personalized drug treatment choices for each patient.
About AssureRx Health, Inc.
AssureRx Health, Inc. is a personalized medicine company that specializes in pharmacogenomics dedicated to helping physicians determine the right drug for individual patients suffering from neuropsychiatric and other disorders. The company was founded to commercialize industry-leading personalized medicine technology for neuropsychiatric disorders. Mayo Clinic and Cincinnati Children’s Hospital Medical Center are equity holders and technology collaborators.